Rubix LS Information

Most late-stage failures are not surprises. They trace back to evidence that was too narrow, endpoints that could not carry a confirmatory trial, and subgroup assumptions nobody tested before capital and conviction hardened around a program. Rubix LS is a clinical research and evidence-generation company that closes that gap early. We design studies, run trials, and build real-world evidence from 25M+ integrated patient records covering the populations, geographies and disease presentations standard databases miss — with mobile clinical sites that hold 90% retention in hard-to-reach communities. What that evidence changes: Which endpoint can actually answer the therapeutic question Which population should carry the signal into Phase III Which indication and payer case are defensible Whether an asset deserves the next round of investment How we work: Translational Research & Evidence Strategy — feasibility, biomarker strategy, endpoint selection, integrated evidence plans. Oncology, rare disease, infectious disease. Clinical Trial Services — full-service CRO from pre-clinical through Phase II, partnered Phase III/IV; protocol, regulatory, sites, recruitment, safety, data management, biostatistics. Federal Health & Public Health Research — infectious disease surveillance, biodefense and community health programs with HHS, CDC, DoD and partnered agencies. Every week we publish an Evidence Brief on one program decision the evidence could have changed earlier. Follow along — or talk to our team about yours at rubixls.com.